ES2890453T3 - Carbamatos de galantamina para el tratamiento del autismo - Google Patents

Carbamatos de galantamina para el tratamiento del autismo Download PDF

Info

Publication number
ES2890453T3
ES2890453T3 ES15769592T ES15769592T ES2890453T3 ES 2890453 T3 ES2890453 T3 ES 2890453T3 ES 15769592 T ES15769592 T ES 15769592T ES 15769592 T ES15769592 T ES 15769592T ES 2890453 T3 ES2890453 T3 ES 2890453T3
Authority
ES
Spain
Prior art keywords
galantamine
analog
group
mecp2
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15769592T
Other languages
English (en)
Spanish (es)
Inventor
Bonnie M Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synaptec Development LLC
Original Assignee
Synaptec Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synaptec Development LLC filed Critical Synaptec Development LLC
Application granted granted Critical
Publication of ES2890453T3 publication Critical patent/ES2890453T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES15769592T 2014-03-25 2015-03-24 Carbamatos de galantamina para el tratamiento del autismo Active ES2890453T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461969896P 2014-03-25 2014-03-25
PCT/US2015/022220 WO2015148487A1 (fr) 2014-03-25 2015-03-24 Traitement de l'autisme

Publications (1)

Publication Number Publication Date
ES2890453T3 true ES2890453T3 (es) 2022-01-19

Family

ID=54196299

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15769592T Active ES2890453T3 (es) 2014-03-25 2015-03-24 Carbamatos de galantamina para el tratamiento del autismo

Country Status (6)

Country Link
US (1) US10561665B2 (fr)
EP (1) EP3122363B1 (fr)
JP (2) JP6796056B2 (fr)
CA (1) CA2944019C (fr)
ES (1) ES2890453T3 (fr)
WO (1) WO2015148487A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148480A1 (fr) 2014-03-25 2015-10-01 Emicipi Llc Traitement du syndrome de rett

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020852A2 (fr) 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
US8557310B2 (en) 2005-04-13 2013-10-15 Stephen C. Perry Composition to retard the onset of symptoms of alzheimer's disease
US20090253654A1 (en) * 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US8155701B2 (en) * 2007-11-07 2012-04-10 Telefonaktiebolaget Lm Ericsson (Publ) Uplink radio frames apportioned for plural multiple access technologies
ES2463715T3 (es) * 2008-04-14 2014-05-29 Neurodyn Life Sciences Inc. Derivados de galantamina como profármacos para el tratamiento de enfermedades del cerebro humano
PE20120324A1 (es) 2009-05-11 2012-04-17 Envivo Pharmaceuticals Inc Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
CA2768668A1 (fr) * 2009-07-23 2011-01-27 Shire Llc Promedicaments a base de l'acide amine galantamine et de peptides et utilisations de ceux-ci

Also Published As

Publication number Publication date
JP2020186254A (ja) 2020-11-19
CA2944019C (fr) 2022-08-02
EP3122363A1 (fr) 2017-02-01
JP6796056B2 (ja) 2020-12-02
CA2944019A1 (fr) 2015-10-01
EP3122363A4 (fr) 2017-11-08
JP2017510640A (ja) 2017-04-13
US20170173038A1 (en) 2017-06-22
EP3122363B1 (fr) 2021-06-23
WO2015148487A1 (fr) 2015-10-01
US10561665B2 (en) 2020-02-18

Similar Documents

Publication Publication Date Title
ES2610508T3 (es) Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
ES2678794T3 (es) Terapia para trastornos neurológicos basada en baclofeno y acamprosato
ES2897453T3 (es) Aplicación de R-ketamina y sal de la misma como productos farmacéuticos
Barros et al. Participation of hippocampal nicotinic receptors in acquisition, consolidation and retrieval of memory for one trial inhibitory avoidance in rats
Wang et al. Levodopa improves learning and memory ability on global cerebral ischemia-reperfusion injured rats in the Morris water maze test
US20150313913A1 (en) Positive allosteric modulators of the gaba-a receptor in the treatment of autism
ES2711973T3 (es) Uso de compuestos farmacéuticos activos para el tratamiento de afecciones del sistema nervioso central
ES2891306T3 (es) Combinación de ibudilast y riluzol y métodos de utilización de los mismos
Kazkayasi et al. Intranasal metformin treatment ameliorates cognitive functions via insulin signaling pathway in ICV-STZ-induced mice model of Alzheimer's disease
ES2886873T3 (es) Composiciones farmacéuticas para mejorar el rendimiento de la memoria
André et al. Nicotine ameliorates NMDA receptor antagonist-induced deficits in contextual fear conditioning through high-affinity nicotinic acetylcholine receptors in the hippocampus
Auchter et al. Therapeutic benefits of methylene blue on cognitive impairment during chronic cerebral hypoperfusion
Jeon et al. Agmatine relieves behavioral impairments in Fragile X mice model
Li et al. Increased extrasynaptic GluN2B expression is involved in cognitive impairment after isoflurane anesthesia
Shavit-Stein et al. Unexpected role of stress as a possible resilience mechanism upon mild traumatic brain injury (mTBI) in mice
ES2890453T3 (es) Carbamatos de galantamina para el tratamiento del autismo
Demeter et al. Paradox effects of kynurenines on LTP induction in the Wistar rat. An in vivo study
BR112021005932A2 (pt) composição farmacêutica, combinação farmacêutica neuroprotetora, inibidor da acetilcolinesterase e agonista receptor de 5-ht4
Wu et al. Attenuation of toluene-induced brain stimulation reward enhancement and behavioral disturbances by N-acetylcysteine in mice
JP6992004B2 (ja) パーキンソン病患者において転倒を低減するためのアセチルコリンエステラーゼ阻害剤およびイダロピルジンの使用
Abdelzaher et al. The novel potential therapeutic utility of montelukast in alleviating autistic behavior induced by early postnatal administration of thimerosal in mice
Song et al. Double triggers, nasal induction of a Parkinson’s disease mouse model
US20240024293A1 (en) Nomethiazoles as a treatment for rett syndrome
CA3194818A1 (fr) Administration intranasale de suramine pour le traitement de troubles du systeme nerveux
Yao et al. PBA regulates neurogenesis and cognition dysfunction after repeated electroconvulsive shock in a rat model